key: cord-1002289-n9adiu9z
authors: Betsch, Devin; Freund, Paul R.
title: NEURO-OPHTHALMOLOGICAL MANIFESTATIONS OF NOVEL CORONAVIRUS
date: 2021-04-28
journal: Adv Ophthalmol Optom
DOI: 10.1016/j.yaoo.2021.04.017
sha: 89e95d1776387494b467af3c97b9aab29d387903
doc_id: 1002289
cord_uid: n9adiu9z

The novel Coronavirus disease 2019 (SARS-CoV-2/COVID-19) has multiple systemic manifestations, including disease entities relevant to neuro-ophthalmologic practices, including Ischemic and hemorraghic strokes, cranial nerve palsies, Miller Fisher and Guillan-Barre syndrome, optic neuritis, and intracranial hypertension. The delivery of health care in Neuro-ophthalmology clinics has evolved to expand the role of telehealth and new management decisions regarding immunosuppresive treatment of pre-existing neuro-ophthalmologic diseases, and prone positioning causing ischemic optic neuropathy. This review article aims to summarize the associations between COVID-19 and neuro-ophthalmologic conditions based on a systematic review of current literature on the topic.

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been found to have many systemic manifestations.

Of these, ocular presentations associated with COVID-19 have been identified as clinicians' familiarity with the disease has increased since the start of the pandemic in early 2020, with a rapidly evolving body of literature. The field of neuro-ophthalmology has been affected, due to both neuro-ophthalmic manifestations of COVID-19, as well as adaptations in delivery of health care and treatment of pre-existing conditions. Literature emerging on the topic of COVID-19-related thrombotic events has highlighted the relationship between coronavirus infection and hypercoagulability. The increased risk of both arterial and venous thrombosis is thought to be due to inflammation, platelet activation, endothelial dysfunction, and stasis. 1 Patients with COVID-19 infections have been found to have elevated D-dimer levels, thrombocytopenia, and prolonged prothrombin time (PT)/international normalized ratio (INR). [2] [3] [4] [5] [6] [7] These patients can develop venous thromboembolism, myocardial infarction, stroke, and limb ischemia, even when anticoagulated. 1, [8] [9] [10] [11] It is possible that a similar mechanism may account for some of the suspected neuroophthalmologic associations, such as cranial neuropathies, which often occur in the context of ischemia.

Beyond the neuro-ophthalmic conditions that have been associated with COVID-19 infection, neuro-ophthalmologists care of uninfected patients also has been drastically altered, with a significant shift towards tele-medicine as well as optimizing the management of pre-existing conditions given the concern regarding immunosuppression during the current COVID-19 pandemic.

J o u r n a l P r e -p r o o f Article Body:

A. Neuro-ophthalmic Presentations

Cranial nerve abnormalities, including anosmia and hypogeusia, have been reported in association with COVID-19, and are accepted symptoms of infection. Based on these findings, it is postulated that the olfactory bulb may serve as an entry point for SARS-CoV-2 into the nervous system. 12 Though less common, there have been reports of isolated oculomotor, trochlear, and abducens nerve palsies in patients with COVID-19.

Faucher et al. documented an isolated, partial left oculomotor nerve palsy (impaired adduction and supraduction of the left eye without ptosis or mydriasis) in a 21-year-old man with no other comorbidities that developed 16 days after developing respiratory symptoms. 13 He had a positive PCR testing to SARS-CoV-2. His clinical course involved 6 days of intubation and ICU care.

MRI showed a few arterial microectasia, but no involvement of the oculomotor nerve. Extensive serologic testing was negative. His symptoms of diplopia resolved within 7 days. Belghmaidi et al. described a similar presentation with a partial left oculomotor nerve palsy (lacking ptosis or mydriasis) in a 23-year-old women with no medical comorbidities, preceded by 3 days of fever, anosmia, and cough. 14 Her MRI/MRA imaging and serologic testing for a cause was unremarkable apart from positive PCR testing for SARS-CoV-2. She recovered within 6 days of onset. Fitzpatrick et al. reported a 67-year-old male with no medical comorbidities who developed a pupil-sparing oculomotor nerve palsy 4 days after being diagnosed with COVID-19. 15 His MRI brain showed only non-specific microvascular changes and serology was noncontributory. His diplopia improved over 1 month, and the nerve palsy had completely resolved by 2 months. Similarly, Wei et al. reported a 62-year-old man who presented with a 5-day J o u r n a l P r e -p r o o f history of an isolated pupil-sparing oculomotor nerve palsy with complete ptosis and loss of adduction and supraduction. 16 His medical history was significant for well-controlled type 2 diabetes mellitus, hypertension, and a prior lacunar infarct, but he did not have any respiratory symptoms on presentation. MRI/MRA imaging did not show any acute infarct or aneurysmal cause. He developed dyspnea on day 2 of his admission and was confirmed to have COVID-19 before rapidly deteriorating and passing away on day 12.

Paresis of the trochlear nerve also has been reported. Oliveira et al. report a case of a 69-year-old Caucasian male with a history of hypertension who presented with fever, abdominal pain, chest pain without cough or dyspnea, and a mild occipital headache. 17 Eleven days after the onset of symptoms, he woke with worsening headache and acute onset of binocular diplopia. His neurological examination was consistent with bilateral trochlear nerve palsies. PCR testing was positive for COVID-19. An MRI with angiography and vessel wall imaging showed findings consistent with vasculitis affecting the vertebrobasilar system and fourth cranial nerve nuclei.

His diplopia resolved after a five-day course of IV methylprednisolone.

Likewise, isolated, unilateral abducens nerve palsies have been reported in patients with active SARS-CoV-2 infections. One case involved an otherwise healthy 32-year-old man, who developed binocular horizontal diplopia after three days of progressively worsening upper respiratory tract infectious symptoms. 18 He was ultimately hospitalized for treatment of acute respiratory failure and tested positive for SARS-CoV-2. Five weeks after the onset of diplopia, an ocular examination confirmed a complete left abducens nerve palsy, and MRI imaging at that time showed atrophy of the left lateral rectus consistent with denervation of the muscle. The remainder of his ophthalmologic examination was within normal limits.

Another case involved a 71-year-old woman who presented with cough and fever several days prior to developing diplopia. 19 She was found to have a complete abducens nerve palsy of the right eye. Nasal swab for SARS-CoV-2 PCR was positive. Axial T1 fat-saturated postcontrast MR sequences showed bilateral enhancement of the optic nerve sheaths and Tenon's capsule.

She was treated with hydroxychloroquine. On follow up two weeks after her initial presentation, she reported subjective improvement in her diplopia.

Two additional brief reports documented isolated abducens nerve palsies in SARS-CoV-2 PCR positive patients: one in a 43-year-old female who had negative serologic studies for other infectious and inflammatory causes and a normal contrast-enhanced MRI study of the brain and orbits; and the other a 52-year-old man who was only seen via telehealth consultation and declined further investigations. 20 Follow-up wasn't provided for the 43-year-old patient, but the 52-year-old had a resolution of his abducens nerve palsy 14 days after onset.

All but one of the patients with cranial nerve palsies had developed upper respiratory tract infectious symptoms several days prior to the onset of diplopia. MRI findings were varied, making establishment of a potential mechanism for SARS-CoV-2 causing cranial nerve palsies somewhat challenging. Current hypotheses include direct viral invasion and injury of the nervous system verses indirect autoimmune and neuroinflammatory pathways. 21, 22 The speed of recovery appears to be quite rapid: 2/3 of the patients with CN3 palsies recovered within 2 weeks (and the third by 2 months); the patient with the CNS vasculitis and bilateral CN4 palsies recovered within 5 days; and 2/3 of the patients with CN6 palsies with reported follow-up had rapid recovery within 14 days of symptom onset. This is comparable to the speed of recovery from anosmia and ageusia, suggesting a common underlying pathophysiology. 23 Electrophysiological studies demonstrated segmental demyelinating polyneuropathy.

Cerebrospinal fluid analysis showed albuminocytologic dissociation, consistent with Guillain-Barré. Her neurological symptoms significantly improved with intravenous immunoglobulin. 26 Dinkin et al. reported a 36-year-old man with a history of infantile strabismus who presented with diplopia, left ptosis, and mydriasis, consistent with a left oculomotor nerve palsy. 19 He also had bilateral abduction deficits suggestive of abducens nerve palsies, lower limb hyporeflexia and hypesthesia, and gait ataxia. He had experienced self-limited cough, myalgias, and fever 4 days prior, and was positive for COVID-19. His MRI showed enlargement and enhancement of the left oculomotor nerve. He was admitted to the hospital and treated for both presumed Miller-Fisher syndrome (ganglioside antibody negative) and COVID-19, with IV immunoglobulin for three days and hydroxychloroquine for five days, respectively. His neurological deficits had improved at the time of discharge.

Gutierrez-Ortiz et al. described two cases of COVID-19 associated with MFS and polyneuritis cranialis. 27 The first was a 50-year-old man who presented with Miller-Fisher syndrome. , PCR J o u r n a l P r e -p r o o f was positive for SARS-CoV-2. His neurologic findings consisted of a right internuclear ophthalmoplegia, anosmia, ageusia, ataxia, and areflexia that developed five days after developing fever, malaise, and cough. Interestingly, he was positive for anti-GD1b ganglioside antibodies, rather than anti-GQ1b that is more commonly associated with MFS. He was treated with intravenous immunoglobulin and made a near complete neurological recovery. The second case occurred in a 39-year-old man who was diagnosed with polyneuritis cranialis and COVID-19 after presenting with diarrhea, fever, and malaise, followed three days later by bilateral abducens nerve palsies, ageusia, and areflexia. Ganglioside antibody testing was not performed.

He was treated with acetaminophen and had complete resolution of symptoms. Both patients had albuminocytologic dissociation on initial work up.

Of the five cases described, four developed neurological symptoms after the onset of viral upper respiratory symptoms, within a range of 3 days to 3 weeks. One presented with physical exam findings consistent with Guillain-Barré prior to the onset of any symptoms known to be associated with SARS-CoV-2 infection. All had favourable outcomes despite their diagnoses of COVID-19. It is suspected that these cases of Guillain-Barré and Miller-Fisher syndrome represents a similar immune response to other post-viral cases of GBS/MFS due to molecular mimicry from the COVID-19 spike protein. 27, 28 The short time frame between onset of COVID-19 symptoms and GBS/MFS may be due to an underestimation of the actual date of infection because of the asymptomatic incubation period between SARS-CoV-2 infection and development of respiratory symptoms.

There have been several reports of optic neuritis in patients with concomitant SARS-CoV-2 infection and no known prior history of autoimmune or demyelinating disease. Two cases of J o u r n a l P r e -p r o o f inflammatory optic neuritis have occurred in the setting of panuveitis. One involved a 60-yearold woman who presented with left eye pain, redness, and blurred vision two weeks following a respiratory infection with associated sinusitis as well as conjunctivitis. 29 On exam, she was found to have panuveitis and optic disc swelling. Work up for toxoplasmosis, HIV, and syphilis were negative. She developed worsening respiratory symptoms ten days after initial presentation and ultimately was diagnosed with COVID-19 after confirmatory PCR testing. While her visual acuity significantly improved after treatment with hydroxychloroquine and systemic steroids, she had significant optic nerve atrophy at the time of discharge.

A second report described a woman in her late 50s who was admitted for bilateral COVID-19+ pneumonia and developed a red eye with decreased vision (hand motion acuity), pain with extraocular movements, and a relative afferent pupillary defect. 30 It has been previously established that SARS-CoV-2 enters cells by binding to the ACE2 receptor. 35, 36 Given that ACE2 has been found on choroidal cells and neurons, direct viral invasion has been proposed as a mechanism for the development of uveitis and optic neuritis.

The optic nerve atrophy that was found in the patients who recovered from panuveitis with optic neuritis could potentially be explained by an ischemic event, as the virus has a documented prothrombotic effect and endotheliumtropism. 29 In the case of the patients with MOG-associated and MS-associated optic neuritis, as well as ADEM, the relationship between viral prodrome and para-or post-infectious demyelinating syndromes has been well established in the literature. 37, 38 Molecular mimicry is the most widely accepted mechanism, whereby viral antigens initiate a robust immune response against endogenous CNS proteins, including MOG and myelin. 38 However, the patient who was diagnosed with MS after developing optic neuritis had radiographic evidence of both active and inactive demyelinating lesions, suggesting that her MS disease likely preceded her SARS-CoV-2 infection, although one can't exclude that the infection didn't trigger the episode of optic neuritis. 

Cerebral venous sinus thrombosis (CVST) is a rare cause of secondary intracranial hypertension but is a significant concern given that SAR-CoV-2 induces a hypercoagulable state and the risk of significant morbidity if CVST is unrecognized or untreated. 42 Mutiple reports exists of CVST associated with COVID, but there is a paucity of ophthalmic examinations in the reports to assess for papilledema and other findings of neuro-ophthalmic interest. This may reflect that these patients were admitted to high acuity COVID-19 wards with reduced access to ophthalmology consultations. [43] [44] [45] Practitioners should have a high index of suspicion to rule out CVST with venography and ensure appropriate anticoagulation is instituted.

Beyond the direct causative effect of SARS-CoV-2 inducing intracranial hypertension through the aforementioned mechanisms, changes in health-care delivery and biopsychosocial effects of pandemic restrictions have been associated with more severe presentations or worsening disease in patients with new or previously diagnosed IIH, respectively. 46 A tertiary center in Birmingham, UK found a 4.7x increase in their rate of CSF diversion procedures which included 21% of their patients with newly diagnosed IIH. Conclusions were limited due to the retrospective nature of the report, but it is likely a combination of decreased or delayed access to emergency care, limited clinical examinations (as guidelines have suggested minimizing fundoscopy and visual field testing to minimize exposures for health care workers), as well as weight gain due to pandemic lockdowns and increased anxiety and depression in patients. This highlights the importance of ensuring that clinical care for non-COVID-19 related presentations isn't compromised as health care systems evolve and adapt to COVID-19 restrictions.

In addition to the ischemic and hemorrhagic cerebrovascular complications of COVID-19, there is a higher rate of posterior reversible encephalopathy syndrome (PRES) in the setting of acute J o u r n a l P r e -p r o o f attributed to prone positioning in COVID-19 patients, heightened awareness has been recommended, given the risk of significant morbidity.

The COVID-19 pandemic posed a dilemma among patients and health care staff alike in regard to the use of immunosuppressive agents. Early in the pandemic, there was concern regarding increased risk of SARS-CoV-2 infection in patients with neuromyelitis optica spectrum disorders (NMOSD) and other autoimmune conditions being treated with immunosuppressive agents, due to the associated increased susceptibility to infection. This concern was speculative and given that no data existed at the time to support this hypothesis, and it was not recommended to prophylactically change treatment regimens. 52 As the pandemic has progressed, these concerns have not been borne out, and evidence suggests patients on immunosuppressive agents aren't at higher risk of COVID-19. 53 Salama et al conducted a survey that was distributed amongst 186 randomly selected patients with NMOSD to gain more understanding of patient perspectives surrounding use of immunosuppressive therapies during the COVID-19 pandemic. 54 The majority of patients (85%)

had not considered stopping their medication, though some had delayed rituximab infusions. Approximately 1/3 of patients were maintaining in person clinic visits, while the remainder were communicating with their health care provider via telephone, email, or telemedicine. Overall, it was concluded that the majority of patients did not alter their medication schedule despite concern about acquiring COVID-19.

In light of the current pandemic, physicians are turning to telehealth as a safer alternative to providing in-person visits. However, the practice of neuro-ophthalmology poses an interesting J o u r n a l P r e -p r o o f challenge to this transition, given the benefit of physical exam findings and timely diagnostic testing on differentiation of benign from sinister underlying etiologies. 55 Certain aspects of the physical exam, such as visual acuity and a testing for an afferent pupillary defect, can be performed by the patient via videoconferencing with detailed instruction. 56, 57 However, fundoscopy and quantification of strabismus currently requires in-person assessment and subtle findings such as nystagmus may be missed depending on the quality of the video connection.

Practical considerations such as lack of access to appropriate technology may preclude the use of telehealth visits in some patients. Interestingly, remote visual field testing has shown similar reliability to Humphrey visual fields in pilot studies but is not yet readily available. 55 Artificial intelligence optic disc analysis and digital fundus photography are on the horizon, but currently cannot replace clinic visits. 58 While consultations often are best served by an office visit, appropriate triaging and prescreening of appointments (for example, to appropriately arrange laboratory testing or imaging by the referring physician) allows telemedicine to reduce the need for in-person visits. 55, 58 Videoconferencing has gained popularity in medical education and research, with entire largescale conferences being held via online platforms. As technology evolves and matches the demand for online visits, it certainly is possible that these innovations will propel us into an era where comprehensive virtual visits become commonplace, pandemic notwithstanding.

J o u r n a l P r e -p r o o f

As more time passes, we are seeing an increasing number of neuro-ophthalmological conditions presenting in patients with SARS-CoV-2. However, true associations and mechanisms are theoretical and based on extrapolations from a limited, though increasing, number of cases. As more data is accumulated, these relationships will become better characterized. One also has to consider the possibility that the timing of COVID-19 infection and the various neuroophthalmologic presentations have overlapped coincidentally, rather than due to the SARS-CoV-2 virus being a causative factor. On the other hand, given the restrictions and attempts to limit exposure to COVID-19 patients with abbreviated physical examinations or lack of manpower due to hospital capacity issues, there may also be under-reporting of subtle neuro-ophthalmic presentations.

This review summarizes what is known about the relationship between SARS-CoV-2 and neuroophthalmology, in hopes that clinicians will have a higher index of suspicion to investigate for concomitant COVID-19 infection in patientsmany of the patients had little or no respiratory symptoms when they developed their neuro-ophthalmic concerns. Given the extensive contact tracing and isolation associated with testing positive for COVID-19, it is also conceivable that patients may underreport these symptoms. Thus, health care providers must remain vigilant and informed on the conditions that may be associated with SARS-CoV-2 infection.

Immunosuppressive medications are still being widely used during the pandemic. There has been no evidence to date to suggest pre-emptively stopping or changing a patient's immunosuppressive therapy during this time. Even those with proven SARS-CoV-2 infection are assessed on a case-by-case basis, taking into account the patient's comorbidities and J o u r n a l P r e -p r o o f relatively severity of the sequelae associated with undertreating their neuro-ophthalmologic disease In regard to the changes in patient care, telehealth has been well received by health care providers and patients alike. There is a need for further research on the topic to analyze cost effectiveness and overall efficacy, as well as validate tools such as visual field testing to allow their implantation in a clinical setting.

J o u r n a l P r e -p r o o f

While these neuro-ophthalmic findings may be unrelated to SARS-CoV-2 infection, health care providers should still consider them as potential manifestations of infection and exercise caution when seeing patients who present with these findings. As more reports of neuro-ophthalmic presentations in the setting of COVID-19 infections are published, the body of evidence from which to draw from will be become more robust. In turn, the quality of data on the topic of neuro-ophthalmology and COVID-19 will improve, such that more definitive conclusions can be drawn about underlying mechanisms of these associations.

J o u r n a l P r e -p r o o f

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and followup

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Laboratory abnormalities in patients with COVID-2019 infection

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19

Large-vessel stroke as a presenting feature of Covid-19 in the young

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Coagulation abnormalities and thrombosis in patients with COVID-19

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Isolated post SARS-CoV-2 diplopia

Third Cranial Nerve Palsy Presenting with Unilateral Diplopia and Strabismus in a 24-Year-Old Woman with COVID-19

Cranial Nerve III Palsy in the setting of COVID 19 Infection

The 2019 novel cornoavirus pneumonia with onset of oculomotor nerve palsy: a case study

Bilateral trochlear nerve palsy due to cerebral vasculitis related to COVID-19 infection

Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19)

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

Isolated Cranial Nerve 6 Palsy in 6 Patients With COVID-19 Infection

Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2

Cranial neuropathies and COVID-19: Neurotropism and autoimmunity

Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Pathogenesis of Guillain-Barré syndrome

Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing

Panuveitis and Optic Neuritis as a Possible Initial Presentation of the Novel Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019-Associated Ocular Neuropathy With Panuveitis: A Case Report

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19

COVID-19-Induced Acute Bilateral Optic Neuritis

Multiple sclerosis following SARS-CoV-2 infection

Acute disseminated encephalomyelitis after SARS-CoV-2 infection

Can the Coronavirus Disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals

Neurotropism of SARS-CoV 2: mechanisms and manifestations

Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features

MBP-PLP fusion proteininduced EAE in C57BL/6 mice

COVID-19 and benign intracranial hypertension: A case report

Pseudotumor cerebri syndrome associated with MIS-C: a case report

Isolated intracranial hypertension associated with COVID-19

Cerebral Venous Sinus Thrombosis in the COVID-19 Pandemic

Cerebral venous thrombosis: A typical presentation of COVID-19 in the young

Cerebral Venous Sinus Thrombosis as a Presentation of COVID-19

Cerebral Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The Literature

Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension

Posterior reversible encephalopathy syndrome in patients with COVID-19

Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: Case report

Hallucinatory Palinopsia in COVID-19-Induced Posterior Reversible Encephalopathy Syndrome

Eye Protection for Patients With

Undergoing Prolonged Prone-Position Ventilation

Ocular Complications in the Prone Position in the Critical Care Setting: The COVID-19 Pandemic

Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis

Tele-Neuro-Ophthalmology: Vision for 20/20 and Beyond

The Virtual Neurologic Exam: Instructional Videos and Guidance for the COVID-19 Era

Tele-Neuro-Ophthalmology During the Age of COVID-19

Neuro-ophthalmology in the Era of COVID-19: Future Implications of a Public Health Crisis